BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36361830)

  • 1. Granulocytic MDSC with Deficient CCR5 Alleviates Lipogenesis and Inflammation in Nonalcoholic Fatty Liver Disease.
    Liao TC; Huang JP; Tsai YT; Shih WC; Juan CC; Hsieh PS; Hung LM; Yu CL
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
    He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
    World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
    Park MJ; Kim DI; Lim SK; Choi JH; Kim JC; Yoon KC; Lee JB; Lee JH; Han HJ; Choi IP; Kim HC; Park SH
    J Hepatol; 2014 Nov; 61(5):1151-7. PubMed ID: 25003952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis.
    Zhao XY; Xiong X; Liu T; Mi L; Peng X; Rui C; Guo L; Li S; Li X; Lin JD
    Nat Commun; 2018 Jul; 9(1):2986. PubMed ID: 30061575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toyocamycin attenuates free fatty acid-induced hepatic steatosis and apoptosis in cultured hepatocytes and ameliorates nonalcoholic fatty liver disease in mice.
    Takahara I; Akazawa Y; Tabuchi M; Matsuda K; Miyaaki H; Kido Y; Kanda Y; Taura N; Ohnita K; Takeshima F; Sakai Y; Eguchi S; Nakashima M; Nakao K
    PLoS One; 2017; 12(3):e0170591. PubMed ID: 28278289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5
    Blattner C; Fleming V; Weber R; Himmelhan B; Altevogt P; Gebhardt C; Schulze TJ; Razon H; Hawila E; Wildbaum G; Utikal J; Karin N; Umansky V
    Cancer Res; 2018 Jan; 78(1):157-167. PubMed ID: 29089297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity.
    Cai Y; Li H; Liu M; Pei Y; Zheng J; Zhou J; Luo X; Huang W; Ma L; Yang Q; Guo S; Xiao X; Li Q; Zeng T; Meng F; Francis H; Glaser S; Chen L; Huo Y; Alpini G; Wu C
    Hepatology; 2018 Jul; 68(1):48-61. PubMed ID: 29315766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y
    J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipose Tissue-Derived CCL5 Enhances Local Pro-Inflammatory Monocytic MDSCs Accumulation and Inflammation via CCR5 Receptor in High-Fat Diet-Fed Mice.
    Chan PC; Lu CH; Chien HC; Tian YF; Hsieh PS
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation.
    Wu X; Zheng H; Yang R; Luan X; Zhang L; Jin Q; Jin Y; Xue J
    Am J Physiol Endocrinol Metab; 2019 Sep; 317(3):E436-E445. PubMed ID: 31211621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity.
    Cao YN; Yue SS; Wang AY; Xu L; Hu YT; Qiao X; Wu TY; Ye M; Wu YC; Qi R
    J Ethnopharmacol; 2022 Jun; 292():115146. PubMed ID: 35304272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Inulin increases the proportion of monocytic myeloid-derived suppressor cells in peripheral blood, liver, spleen and regulates the secretion of plasma inflammatory cytokines in mice with non-alcoholic fatty liver disease].
    Bao T; Wang Z; Zhu L; Lu H; Wang T; Zhang Y; Zhang X; Wang H; Yang S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Mar; 36(3):228-235. PubMed ID: 32389170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis.
    Zhang L; Zhang Z; Li C; Zhu T; Gao J; Zhou H; Zheng Y; Chang Q; Wang M; Wu J; Ran L; Wu Y; Miao H; Zou X; Liang B
    Cell Mol Gastroenterol Hepatol; 2021; 11(3):697-724. PubMed ID: 33075563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis.
    Wu H; Zhang T; Pan F; Steer CJ; Li Z; Chen X; Song G
    J Hepatol; 2017 Apr; 66(4):816-824. PubMed ID: 28025059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1.
    Zhang M; Tang Y; Tang E; Lu W
    Biochem Biophys Res Commun; 2020 Apr; 524(3):716-722. PubMed ID: 32035613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transcription cofactor CRTC1 protects from aberrant hepatic lipid accumulation.
    Kim H
    Sci Rep; 2016 Nov; 6():37280. PubMed ID: 27869139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.